Abstract
Cancer-related fatigue is a pervasive syndrome experienced by a majority of cancer patients undergoing treatment, and muscular dysfunction may be a key component in the development and progression of this syndrome. Doxorubicin (DOX) is a commonly used antineoplastic agent used in the treatment of many cancers. The purpose of this study was to determine the effect of DOX exposure on the function of cardiac, skeletal, and smooth muscle tissues and examine the role accumulation of DOX may play in this process. In these studies, rats were treated with DOX and measurements of cardiac, skeletal, and smooth muscle function were assessed 1, 3, and 5 days after exposure. All muscular tissues showed significant and severe dysfunction, yet there was heterogeneity both in the time course of dysfunction and in the accumulation of DOX. Cardiac and skeletal muscle exhibited a time-dependent progressive decline in function during the 5 days following DOX treatment. In contrast, vascular function showed a decline in function that could be characterized as rapid onset and was sustained for the duration of the 5-day observation period. DOX accumulation was greatest in cardiac tissue, yet all muscular tissues showed a similar degree of dysfunction. Our data suggest that in muscular tissues both DOX-dependent and DOX-independent mechanisms may be involved with the muscular dysfunction observed following DOX treatment. Furthermore, this study highlights the fact that dysfunction of skeletal and smooth muscle may be an underappreciated aspect of DOX toxicity and may be a key component of cancer-related fatigue in these patients.
| Original language | English |
|---|---|
| Pages (from-to) | 177-187 |
| Number of pages | 11 |
| Journal | Journal of Physiology and Biochemistry |
| Volume | 69 |
| Issue number | 2 |
| DOIs | |
| State | Published - Jun 2013 |
| Externally published | Yes |
Fingerprint
All Science Journal Classification (ASJC) codes
- Physiology
- Biochemistry
Cite this
Tissue retention of doxorubicin and its effects on cardiac, smooth, and skeletal muscle function. / Hayward, Reid; Hydock, David; Gibson, Noah; Greufe, Stephanie; Bredahl, Eric; Parry, Traci.
In: Journal of Physiology and Biochemistry, Vol. 69, No. 2, 06.2013, p. 177-187.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Tissue retention of doxorubicin and its effects on cardiac, smooth, and skeletal muscle function
AU - Hayward, Reid
AU - Hydock, David
AU - Gibson, Noah
AU - Greufe, Stephanie
AU - Bredahl, Eric
AU - Parry, Traci
PY - 2013/6
Y1 - 2013/6
N2 - Cancer-related fatigue is a pervasive syndrome experienced by a majority of cancer patients undergoing treatment, and muscular dysfunction may be a key component in the development and progression of this syndrome. Doxorubicin (DOX) is a commonly used antineoplastic agent used in the treatment of many cancers. The purpose of this study was to determine the effect of DOX exposure on the function of cardiac, skeletal, and smooth muscle tissues and examine the role accumulation of DOX may play in this process. In these studies, rats were treated with DOX and measurements of cardiac, skeletal, and smooth muscle function were assessed 1, 3, and 5 days after exposure. All muscular tissues showed significant and severe dysfunction, yet there was heterogeneity both in the time course of dysfunction and in the accumulation of DOX. Cardiac and skeletal muscle exhibited a time-dependent progressive decline in function during the 5 days following DOX treatment. In contrast, vascular function showed a decline in function that could be characterized as rapid onset and was sustained for the duration of the 5-day observation period. DOX accumulation was greatest in cardiac tissue, yet all muscular tissues showed a similar degree of dysfunction. Our data suggest that in muscular tissues both DOX-dependent and DOX-independent mechanisms may be involved with the muscular dysfunction observed following DOX treatment. Furthermore, this study highlights the fact that dysfunction of skeletal and smooth muscle may be an underappreciated aspect of DOX toxicity and may be a key component of cancer-related fatigue in these patients.
AB - Cancer-related fatigue is a pervasive syndrome experienced by a majority of cancer patients undergoing treatment, and muscular dysfunction may be a key component in the development and progression of this syndrome. Doxorubicin (DOX) is a commonly used antineoplastic agent used in the treatment of many cancers. The purpose of this study was to determine the effect of DOX exposure on the function of cardiac, skeletal, and smooth muscle tissues and examine the role accumulation of DOX may play in this process. In these studies, rats were treated with DOX and measurements of cardiac, skeletal, and smooth muscle function were assessed 1, 3, and 5 days after exposure. All muscular tissues showed significant and severe dysfunction, yet there was heterogeneity both in the time course of dysfunction and in the accumulation of DOX. Cardiac and skeletal muscle exhibited a time-dependent progressive decline in function during the 5 days following DOX treatment. In contrast, vascular function showed a decline in function that could be characterized as rapid onset and was sustained for the duration of the 5-day observation period. DOX accumulation was greatest in cardiac tissue, yet all muscular tissues showed a similar degree of dysfunction. Our data suggest that in muscular tissues both DOX-dependent and DOX-independent mechanisms may be involved with the muscular dysfunction observed following DOX treatment. Furthermore, this study highlights the fact that dysfunction of skeletal and smooth muscle may be an underappreciated aspect of DOX toxicity and may be a key component of cancer-related fatigue in these patients.
UR - http://www.scopus.com/inward/record.url?scp=84879418973&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84879418973&partnerID=8YFLogxK
U2 - 10.1007/s13105-012-0200-0
DO - 10.1007/s13105-012-0200-0
M3 - Article
C2 - 22890792
AN - SCOPUS:84879418973
VL - 69
SP - 177
EP - 187
JO - Journal of Physiology and Biochemistry
JF - Journal of Physiology and Biochemistry
SN - 1138-7548
IS - 2
ER -